Drugs / AVX701
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01890213 | Nov 2013 → Jun 2017 | malignant colon neoplasm | Duke University | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00529984 | Sep 2007 → May 2010 | breast cancer, colon carcinoma, lung cancer, malignant pancreatic neoplasm | AlphaVax, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVX701 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00529984 ↗ |
| Modality | Vaccine | “AVX701 Vaccine” NCT01890213 ↗ |
| Route | Intramuscular | “intramuscularly” NCT01890213 ↗ |